Trial Profile
Phase I/II Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ruxolitinib (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Aug 2024.
- 04 Jan 2024 Status changed from active, no longer recruiting to recruiting.
- 13 Dec 2023 Protocol of this study has been amended as this study is now an Phase 1/2 study, Interventional study model changed to sequential, Number of treatment arms changed to 2, Efficacy endpoint has been added, hence trial focus shifted to Tu and Ar, Planned number of patients changed from 20 to 54.